Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve... see more

Recent & Breaking News (NYSEAM:ATNM)

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

PR Newswire December 12, 2025

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

PR Newswire December 1, 2025

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Newsfile November 17, 2025

Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications

PR Newswire November 4, 2025

Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

PR Newswire November 3, 2025

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PR Newswire October 27, 2025

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

PR Newswire October 24, 2025

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PR Newswire October 13, 2025

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

PR Newswire October 13, 2025

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

PR Newswire July 31, 2025

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

PR Newswire June 23, 2025

Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm

PR Newswire June 10, 2025

Lifshitz Law PLLC Announces Investigations of Actinium Pharmaceuticals, Inc. (NYSE: ATNM), SoundHound AI, Inc. (NASDAQ: SOUN), Solaris Energy Infrastructure, Inc. (NYSE: SEI), and Bakkt Holdings, Inc. (NYSE: BKKT)

ACCESS Newswire June 9, 2025

NYSE: ATNM Lawsuit Alert: Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) should Contact the Shareholders Foundation

ACCESS Newswire May 28, 2025

Shareholders of Actinium Pharmaceuticals, Inc. (ATNM): Protect Your Rights Before May 27, 2025 - Contact Levi & Korsinsky

ACCESS Newswire May 27, 2025

ATNM DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important May 27 Deadline in Securities Class Action - ATNM

Newsfile May 27, 2025

Levi & Korsinsky Urges Actinium (ATNM) Shareholders to Act Before Lead Plaintiff Deadline May 27, 2025

ACCESS Newswire May 27, 2025

ATNM DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important May 27 Deadline in Securities Class Action - ATNM

ACCESS Newswire May 27, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Business Wire May 27, 2025

Securities Class Action Lawsuit Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - Levi & Korsinsky Represents Shareholders

ACCESS Newswire May 26, 2025

Podcasts